Systemic lupus erythematosus vasculitis: A current therapeutic overview

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 2, 2004, Pages 87-97

  Toubi, Elias ^a   Kessel, Aharon ^a   Bamberger, Ellen ^a   Golan, Theo Dov ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIMALARIAL AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; CHLOROQUINE; CHLORPROMAZINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC AGENT; DAPSONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FOLIC ACID ANTAGONIST; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MEPACRINE; METHOTREXATE; PHENOBARBITAL; PREDNISOLONE; PROBENECID; RESERPINE; RIFAMPICIN; STEROID; THALIDOMIDE; TRIMETHOPRIM; UNINDEXED DRUG;

ALOPECIA; AMENORRHEA; ANEMIA; ANOREXIA; APHTHOUS STOMATITIS; APLASTIC ANEMIA; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BLADDER CANCER; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG ERUPTION; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ERYTHEMA; EXOPHTHALMOS; FATIGUE; FIBROSING ALVEOLITIS; FIBROSIS; FLUID RETENTION; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT CANCER; GINGIVA HYPERPLASIA; GLAUCOMA; GLUCOSE INTOLERANCE; HEADACHE; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; IMMUNE DEFICIENCY; INCREASED APPETITE; INFERTILITY; INTESTINE PERFORATION; LEUKOPENIA; LIPID STORAGE; LYMPHOMA; MEGALOBLASTIC ANEMIA; METABOLIC DISORDER; MYOPATHY; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PATHOGENESIS; PEPTIC ULCER; PLASMAPHERESIS; PNEUMONIA; POLYNEUROPATHY; PROGNOSIS; PSYCHOSIS; REMISSION; REPRODUCTIVE TOXICITY; REVIEW; SEIZURE; SEPSIS; SKIN BLOOD VESSEL; SKIN DISCOLORATION; STOMACH HEMORRHAGE; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TREMOR; VASCULITIS; VISCERA; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 5144219860     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0036-1     Document Type: Review

References (50)

1. Estes D, Christian CL: The natural history of systemic lupus erythematosus by prospective analysis. Medicine 1971, 50:85-95.
2. Grigor R, Edmonds J, Lewkonia R, et al.: Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 1978, 37:111-128.
3. Rothfield N, Marino C: Studies of repeat skin biopsies of non-lesional skin in patients with systemic lupus erythematosus. Arthritis Rheum 1982, 25:624-630.
4. Hochberg MC: Systemic lupus erythematosus. Rheum Dis Clin North Am 1990, 16:617-639.
5. Drenkard C, Villa AR, Reyes E, et al.: Vasculitis in systemic lupus erythematosus. Lupus 1997, 6:235-242.
6. Flores-Suarez LF, Alacron-Segovia D: Vasculitis in connective tissue disease. Curr Rheumatol Rep 2000, 2:396-401.
7. Gladman DD, Urowitz MD: Systemic lupus erythematosus, clinical features. In Rheumatology. Edited by Kippel JH, Dieppe PA. London: Mosby, 1998:1-18.
8. Gladman DD, Hirani N, Ibanez D, Urowitz MB: Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003, 30:1960-1962.
9. Bresnihan B: Outcome and survival in systemic lupus erythematosus. Ann Rheum Dis 1989, 48:443-445.
10. Molina JF: Systemic lupus erythematosus in males. A study of 107 Latin American patients. Medicine 1996, 75:124-130.
11. Cardinali C, Caproni M, Bernacchi E, et al.: The spectrum of cutaneous manifestations in lupus erythematosus. The Italian experience. Lupus 2000, 9:417-423.
12. McCauliffe DP: Cutaneous lupus erythematosus. Semin Cutan Med Surg 2001, 20:14-26.
13. Yell JA, Mbuagbaw J, Burge SM: Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996, 135:355-362.
14. Asherson RA, Cruz DD, Stephens CJM, et al.: Urticarial vasculitis in connective tissue diseases clinic: patterns, presentations and treatment. Semin Arthritis Rheum 1991, 20:285-296.
15. Ng PP, Tan SH, Tan T: Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 2002, 41:488-490.
16. Moore PM: Vasculitis of the central nervous system. Curr Rheumatol Rep 2000, 2:376-382.
17. Ruggieri AP: Neuropsychiatric lupus: nomenclature, classification, criteria, and other confusional states. Arthritis Rheum 2001, 45:406-409.
18. Omdal R: Some controversies of neuropsychiatric systemic lupus erythematosus. Scand J Rheumatol 2002, 31:192-197.
19. Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus: a clinical-pathological study of 24 cases and review of literature. Medicine (Baltimore) 1968, 47:337-369.
20. Lie JT: Vasculopathy of the antiphospholipid syndrome revisited: thrombosis is the culprit and vasculitis is consort. Lupus 1996, 5:368-371.
21. Mawrin C, Brunn A, Rocken C, Schroder JM: Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol (Berl) 2003, 105:365-372.
22. Specks U: Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001, 13:12-17.
23. Santos-Ocampo AS, Mandell BF, Fessler BJ: Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000, 118:1083-1090.
24. Sultan SM, Ioannou Y, Isenberg DA: A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999, 38:917-932.
25. Geboes K, Dalle I: Vasculitis and gastrointestinal tract. Acta Gastroenterol Belg 2000, 65:204-212.
26. Caso V, Paciaroni M, Parnetti L, et al.: Stroke related to carotid artery dissection in a young patient with Takayasu arteritis, SLE and APS. Cerebrovasc Dis 2002, 13:67-69.
27. Wilson WA, Gharavi EA, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop. Arthritis Rheum 1999, 42:1309-1311.
28. Navarrete MG, Brey RL, Levine SR: Cerebral disease in the antiphospholipid syndrome. In Hughes Syndrome: Antiphospholipid Syndrome. Edited by Khamashta MA. London: Springer-Verlag; 2000:43-58.
29. Sailer M, Burchert W, Ehrenheim C, et al.: Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997, 244:186-193.
30. Cuellar MC, Espinoza LR: Laboratory testing in the evaluation and diagnosis of vasculitis. Curr Rheumatol Rep 2000, 2:417-422.
31. Beaufils M, Kouki F, Mignon F, et al.: Clinical significance of anti-Sm antibodies in systemic lupus erythematosus. Am J Med 1983; 74:201-205.
32. Renaudineau Y, Dugue C, Dueymes M, et al.: Antiendothelial cell antibodies in systemic lupus erythematosus. Autoimmun Rev 2002, 1:365-372.
33. Sen D, Isenberg DA: Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 2003, 12:651-658.
34. Wallace DJ: Antimalarials: the real advance in lupus. Lupus 2001, 10:385-387.
35. Molad Y, Gorshtein A, Wysenbeek AJ, et al.: Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 2002, 11:356-361.
36. Toubi E, Rosner I, Rosenbaum M, et al.: The benefit of combined hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000, 9:92-95.
37. A randomized study of the effect of with drawing hydroxychloroguine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group [no authors listed]. N Engl J Med 1991, 324:150-154.
38. Al-Herz A, Schulzer M, Esdaile JM: Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002, 29:700-706.
39. Karim MY, Ruiz-Irastorza G, Khamashta MA, et al.: Update on therapy-thalidomide in the treatment of lupus. Lupus 2001, 10:188-192.
40. Ossandon A, Cassara EA, Priori R, et al.: Thalidomide: focus on its employment in rheumatic diseases. Clin Exp Rheumatol 2002, 20:709-718.
41. Wolf R: Dapsone: un-approval use or indications. Clin Dermatol 2000, 18:37-53.
42. Fabbri P, Cardinali C, Giomi B, et al.: Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003, 4:449-465.
43. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003, 32:370-377.
44. Levy Y, Sherer Y, Ahmed A, et al.: A study of 20 SLE patients with intravenous immunoglobulin: clinical and serological responses. Lupus 1999, 8:705-712.
45. Perez C, Guarch R, Rodrigo M, et al.: Successful treatment of leukocytoclastic vasculitis and pancytopenia secondary to systemic lupus erythematosus with intravenous immunoglobulin. Br J Dermatol 2002, 147:180-182.
46. Martin-Suarez I, D'Cruz D, Mansoor M, et al.: Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481-487.
47. Houssiau FA, Vasconcelos C, D'Cruz D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131.
48. Ioannou Y, Isenberg DA: Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002, 78:599-606.
49. Petri M: Immunosuppressive drug use in pregnancy. Autoimmunity 2003, 36:51-56.
50. Ruiz-Irastorza G, Khamashta MA, Hughes GR: Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin Investig Drugs 2000, 9:1581-1593.